Clinical Trial Update: Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Phase 3]

View source ↗

Summary

This update reports the results of a Phase 3 study evaluating canakinumab for preventing flares in patients with active systemic juvenile idiopathic arthritis (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare | Phase 3 | Status: COMPLETED | Results posted: 2012-10-16